✦ LIBER ✦

Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome

✍ Scribed by Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi

Book ID: 110008275
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 286 KB
Volume: 141
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bjp.0705751

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dietary treatment of the irritable bowel

Dietary treatment of the irritable bowel syndrome

✍ Peter Whorwell; Richard Lea 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 462 KB

A Non-peptidic photoactivatable antagoni

A Non-peptidic photoactivatable antagonist for mapping the antagonist binding site of the tachykinin NK2 receptor

✍ Ian D. Kersey; Nirmala Bhogal; Dan Donnelly; Colin W.G. Fishwick; John B.C. Find 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 207 KB

Meta-analysis: the treatment of irritabl

Meta-analysis: the treatment of irritable bowel syndrome

✍ D. Lesbros-Pantoflickova; P. Michetti; M. Fried; C. Beglinger; A. L. Blum 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

The Treatment of Irritable Bowel Syndrom

The Treatment of Irritable Bowel Syndrome with Hypnotherapy

✍ Tara E. Galovski; Edward B. Blanchard 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 812 KB

Enteric P2X receptors as potential targe

Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome

✍ James J Galligan 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 209 KB

Novel serotonin type 3 receptor partial

Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

✍ David D. Manning; Christopher L. Cioffi; Alexander Usyatinsky; Kevin Fitzpatrick 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole cores have exhibited nanomolar binding affinity for the h5-HT(3)A receptor. A range of partial agoni